Delcath Reminds Shareholders that the Rights Offering Subscription Period Expires Wednesday, September 26, 2018
13 sept. 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its...
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology
04 sept. 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces Extension of Rights Offering Period to September 26, 2018
28 août 2018 08h33 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Delcath Announces Acceptance of Abstract for Poster Presentation at CIRSE 2018
27 août 2018 09h00 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification
23 août 2018 11h14 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces Pending Expiration to Rights Offering Subscription Period
22 août 2018 09h41 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its...
First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma
21 août 2018 08h52 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial
20 août 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Issues Letter to Stockholders
17 août 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH) (“Delcath” or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic...
Delcath Announces Second Quarter Fiscal 2018 Financial Results
15 août 2018 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces...